Get 40% Off
🤯 This Tech Portfolio is up 29% YTD! Join Now to Get April’s Top PicksGet The Picks – Just 99 USD

Regeneron, Sanofi rheumatoid arthritis drug wins FDA approval

Published 05/22/2017, 06:58 PM
Updated 05/22/2017, 06:58 PM
© Reuters.  Regeneron, Sanofi rheumatoid arthritis drug wins FDA approval

© Reuters. Regeneron, Sanofi rheumatoid arthritis drug wins FDA approval

  • Regeneron Pharmaceuticals (NASDAQ:REGN) and Sanofi (NYSE:SNY) say the FDA approved their Kevzara (sarilumab) biotech drug for treatment of adults with moderate to severely active rheumatoid arthritis.
  • Kevzara will carry a list price of $39K/year for the 200 mg and 150 mg doses, which the companies say is ~30% lower than the list price for the two most widely used rival medicines.
  • The approval is the second recent major regulatory victory for the two companies after their Dupixent treatment for severe atopic dermatitis won FDA approval in March.
  • Now read: Paratek Pharmaceuticals: The 1 Antibiotic Stock To Buy Now


Original article

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.